A response to the letter to the editor on “Management of hepatitis B reactivation in lymphoma patients on rituximab with past hepatitis B exposure: An observational study”
Restricted accessLetterFirst published online September, 2018
A response to the letter to the editor on “Management of hepatitis B reactivation in lymphoma patients on rituximab with past hepatitis B exposure: An observational study”
TerraultNALokASMcMahonBJet al.Update on prevention, diagnosis, and treatment and of chronic hepatitis B: AASLD 2018 Hepatitis B Guidance. Hepatology2018; 67: 1560–1599.
2.
Yeo D, Hossain I, Lim ST, Farid M, Tao M, Quek R, Tang T, Chan A. Management of hepatitis B reactivation in lymphoma patients on rituximab with past hepatitis B exposure: An observational study. J Oncol Pharm Pract. Epub ahead of print 19 March 2018. doi: 10.1177/1078155218763039.
3.
TerraultNABzowejNHChangK-Met al.AASLD guidelines for treatment of chronic hepatitis B. Hepatology2016; 63: 261–283.
4.
PaulSDicksteinASaxenaAet al.Role of surface antibody in hepatitis B reactivation in patients with resolved infection and hematologic malignancy: a meta-analysis. Hepatology2017; 66: 379–388.
5.
Ekstrom VSM, Tang TPL, Chan A, et al. Monitoring of subjects with previous Hepatitis B exposure on Rituximab for Hepatitis B reactivation and on demand treatment for Hepatitis B reactivation is safe and reduces cost. In: The International Liver Congress. Paris, France: European Association for the Study of the Liver; 2018: Abstract FRI-297.
6.
RubinLGLevinMJLjungmanPet al.2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis2014; 58: 309–318.
